Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]TK Ghosh, J Bian and DL Gill: Intracellular calcium release mediated by sphingosine derivatives generated in cells. Science, 248 (4963), 1653-6 (1990)

  • [2]H Zhang, NN Desai, A Olivera, T Seki, G Brooker and S Spiegel: Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol, 114(1), 155-67 (1991)

  • [3]Y Sadahira, F Ruan, S Hakomori and Y Igarashi: Sphingosine 1-phosphate, a specific endogenous signaling molecule controlling cell motility and tumor cell invasiveness. Proc Natl Acad Sci U S A, 89(20), 9686-90 (1992)

  • [4]GT Kunkel, M Maceyka, S Milstien and S Spiegel: Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov, 12(9), 688-702 (2013)

  • [5]XLiu, QH Zhang and GH Yi: Regulation of metabolism and transport of sphingosine-1-phosphate in mammalian cells. Mol Cell Biochem, 363(1-2), 21-33 (2012)

  • [6]K Takabe, SW Paugh, S Milstien and S Spiegel: “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev, 60(2), 181-95 (2008)

  • [7]YA Hannun, C Luberto and KM Argraves: Enzymes of Sphingolipid Metabolism: From Modular to Integrative Signaling. Biochemistry, 40(16), 4893-4903 (2001)

  • [8]RA Claus, MJ Dorer, AC Bunck and HP Deigner: Inhibition of sphingomyelin hydrolysis: targeting the lipid mediator ceramide as a key regulator of cellular fate. Curr Med Chem, 16(16), 1978-2000 (2009)

  • [9]N Bartke and YA Hannun: Bioactive sphingolipids: metabolism and function. J Lipid Res, 50 Suppl, S91-6 (2009)

  • [10]PS Jolly, M Bektas, KR Watterson, H Sankala, SG Payne, S Milstien and S Spiegel: Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors. Blood, 105(12), 4736-4742 (2005)

  • [11]VA Blaho and T Hla: An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res, 55(8), 1596-1608 (2014)

  • [12]J Chun, T Hla, KR Lynch, S Spiegel and WH Moolenaar: International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev, 62(4), 579-87 (2010)

  • [13]S Schwalm, J Pfeilschifter and A Huwiler: Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases. Basic Clin Pharmacol Toxicol, 114(1), 44-9 (2014)

  • [14]T Hla and V Brinkmann: Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Neurology, 76(8 Suppl 3), S3-8 (2011)

  • [15]KA Orr Gandy and LM Obeid: Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. Biochim Biophys Acta, 1831(1), 157-66 (2013)

  • [16]T Kohama, A Olivera, L Edsall, MM Nagiec, R Dickson and S Spiegel: Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem, 273(37), 23722-8 (1998)

  • [17]H Liu, M Sugiura, VE Nava, LC Edsall, K Kono, S Poulton, S Milstien, T Kohama and S Spiegel: Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem, 275(26), 19513-20 (2000)

  • [18]M Maceyka, KB Harikumar, S Milstien and S Spiegel: Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol, 22(1), 50-60 (2012)

  • [19]M Nagahashi, K Takabe, KP Terracina, D Soma, Y Hirose, T Kobayashi, Y Matsuda and T Wakai: Sphingosine-1-phosphate transporters as targets for cancer therapy. Biomed Res Int, 2014, 651727 (2014)

  • [20]K Takabe and S Spiegel: Export of sphingosine-1-phosphate and cancer progression. J Lipid Res, 55(9), 1839-46 (2014)

  • [21]T Nishi, N Kobayashi, Y Hisano, A Kawahara and A Yamaguchi: Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim Biophys Acta, 1841(5), 759-65 (2014)

  • [22]M Maceyka, H Sankala, NC Hait, H Le Stunff, H Liu, R Toman, C Collier, M Zhang, LS Satin, AH Merrill, Jr., S Milstien and S Spiegel: SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem, 280(44), 37118-29 (2005)

  • [23]A Sugiyama, NN Aye, Y Yatomi, Y Ozaki and K Hashimoto: Effects of sphingosine 1-phosphate, a naturally occurring biologically active lysophospholipid, on the rat cardiovascular system. Jpn J Pharmacol, 82(4), 338-42 (2000)

  • [24]MG Sanna, J Liao, E Jo, C Alfonso, MY Ahn, MS Peterson, B Webb, S Lefebvre, J Chun, N Gray and H Rosen: Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem, 279(14), 13839-48 (2004)

  • [25]A Sugiyama, Y Yatomi, Y Ozaki and K Hashimoto: Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res, 46(1), 119-25 (2000)

  • [26]CK Means, S Miyamoto, J Chun and JH Brown: S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. J Biol Chem, 283(18), 11954-63 (2008)

  • [27]K Budde, RL Schmouder, R Brunkhorst, B Nashan, PW Lucker, T Mayer, S Choudhury, A Skerjanec, G Kraus and HH Neumayer: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol, 13(4), 1073-83 (2002)

  • [28]J Guo, KL MacDonell and WR Giles: Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch, 438(5), 642-8 (1999)

  • [29]EE Egom, P Kruzliak, V Rotrekl and M Lei: The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue. J Cell Mol Med, 19(7), 1729-34 (2015)

  • [30]L Koyrakh, MI Roman, V Brinkmann and K Wickman: The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant, 5(3), 529-36 (2005)

  • [31]M Bunemann, B Brandts, DM zu Heringdorf, CJ van Koppen, KH Jakobs and L Pott: Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1-phosphate. J Physiol, 489 (Pt 3), 701-7 (1995)

  • [32]LK Landeen, DA Dederko, CS Kondo, BS Hu, N Aroonsakool, JH Haga and WR Giles: Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. Am J Physiol Heart Circ Physiol, 294(2), H736-49 (2008)

  • [33]M Yamada: The role of muscarinic K(+) channels in the negative chronotropic effect of a muscarinic agonist. J Pharmacol Exp Ther, 300(2), 681-7 (2002)

  • [34]EH Demont, BI Andrews, RA Bit, CA Campbell, JW Cooke, N Deeks, S Desai, SJ Dowell, P Gaskin, JR Gray, A Haynes, DS Holmes, U Kumar, MA Morse, GJ Osborne, T Panchal, B Patel, A Perboni, S Taylor, R Watson, J Witherington and R Willis: Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate. ACS Med Chem Lett, 2(6), 444-9 (2011)

  • [35]P Gergely, B Nuesslein-Hildesheim, D Guerini, V Brinkmann, M Traebert, C Bruns, S Pan, NS Gray, K Hinterding, NG Cooke, A Groenewegen, A Vitaliti, T Sing, O Luttringer, J Yang, A Gardin, N Wang, WJ Crumb, Jr., M Saltzman, M Rosenberg and E Wallstrom: The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol, 167(5), 1035-47 (2012)

  • [36]JN Lorenz, LJ Arend, R Robitz, RJ Paul and AJ MacLennan: Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am J Physiol Regul Integr Comp Physiol, 292(1), R440-6 (2007)

  • [37]JS Karliner, N Honbo, K Summers, MO Gray and EJ Goetzl: The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol, 33(9), 1713-7 (2001)

  • [38]R Tao, J Zhang, DA Vessey, N Honbo and JS Karliner: Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res, 74(1), 56-63 (2007)

  • [39]R Tao, HE Hoover, J Zhang, N Honbo, CC Alano and JS Karliner: Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitization. J Cardiovasc Pharmacol, 53(6), 486-94 (2009)

  • [40]J Zhang, N Honbo, EJ Goetzl, K Chatterjee, JS Karliner and MO Gray: Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol, 293(5), H3150-8 (2007)

  • [41]KM Argraves and WS Argraves: HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res, 48(11), 2325-33 (2007)

  • [42]R Tao, HE Hoover, N Honbo, M Kalinowski, CC Alano, JS Karliner and R Raffai: High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol, 298(3), H1022-8 (2010)

  • [43]M Wang, L Lu, Y Liu, G Gu and R Tao: FTY720 attenuates hypoxia-reoxygenation-induced apoptosis in cardiomyocytes. Exp Mol Pathol, 97(2), 218-24 (2014)

  • [44]EE Egom, TM Mohamed, MA Mamas, Y Shi, W Liu, D Chirico, SE Stringer, Y Ke, M Shaheen, T Wang, S Chacko, X Wang, RJ Solaro, F Fath-Ordoubadi, EJ Cartwright and M Lei: Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol, 301(4), H1487-95 (2011)

  • [45]H Yu, X Che, X Xu, M Zheng, Y Zhao, W He, J Yu, J Xiong and W Li: Insulin Protects Apoptotic Cardiomyocytes from Hypoxia/Reoxygenation Injury through the Sphingosine Kinase/Sphingosine 1-Phosphate Axis. PLoS ONE, 8(12), e80644 (2013)

  • [46]ZQ Jin, HZ Zhou, P Zhu, N Honbo, D Mochly-Rosen, RO Messing, EJ Goetzl, JS Karliner and MO Gray: Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol, 282(6), H1970-7 (2002)

  • [47]S Lecour, RM Smith, B Woodward, LH Opie, L Rochette and MN Sack: Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol, 34(5), 509-18 (2002)

  • [48]EE Egom, Y Ke, H Musa, TM Mohamed, T Wang, E Cartwright, RJ Solaro and M Lei: FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol, 48(2), 406-14 (2010)

  • [49]DA Vessey, L Li, N Honbo and JS Karliner: Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre-and postconditioning. Am J Physiol Heart Circ Physiol, 297(4), H1429-35 (2009)

  • [50]EE Egom, MA Mamas, S Chacko, SE Stringer, V Charlton-Menys, M El-Omar, D Chirico, B Clarke, L Neyses, JK Cruickshank, M Lei and F Fath-Ordoubadi: Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. Front Physiol, 4, 130 (2013)

  • [51]DH Deutschman, JS Carstens, RL Klepper, WS Smith, MT Page, TR Young, LA Gleason, N Nakajima and RA Sabbadini: Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J, 146(1), 62-8 (2003)

  • [52]ZQ Jin, JS Karliner and DA Vessey: Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res, 79(1), 134-40 (2008)

  • [53]ZQ Jin, J Zhang, Y Huang, HE Hoover, DA Vessey and JS Karliner: A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res, 76(1), 41-50 (2007)

  • [54]P Bandhuvula, N Honbo, GY Wang, ZQ Jin, H Fyrst, M Zhang, AD Borowsky, L Dillard, JS Karliner and JD Saba: S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart. Am J Physiol Heart Circ Physiol, 300(5), H1753-61 (2011)

  • [55]DA Vessey, L Li, ZQ Jin, M Kelley, N Honbo, J Zhang and JS Karliner: A sphingosine kinase form 2 knockout sensitizes mouse myocardium to ischemia/reoxygenation injury and diminishes responsiveness to ischemic preconditioning. Oxid Med Cell Longev, 2011, 961059 (2011)

  • [56]L Gomez, M Paillard, M Price, Q Chen, G Teixeira, S Spiegel and EJ Lesnefsky: A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in PTP-mediated cell survival during cardioprotection. Basic Res Cardiol, 106(6), 1341-53 (2011)

  • [57]DA Vessey, L Li, I Imhof, N Honbo and JS Karliner: FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning. Med Sci Monit Basic Res, 19, 126-32 (2013)

  • [58]U Hofmann, N Burkard, C Vogt, A Thoma, S Frantz, G Ertl, O Ritter and A Bonz: Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. Cardiovasc Res, 83(2), 285-93 (2009)

  • [59]YT Tsukada, MG Sanna, H Rosen and RA Gottlieb: S1P1-selective agonist SEW2871 exacerbates reperfusion arrhythmias. J Cardiovasc Pharmacol, 50(6), 660-9 (2007)

  • [60]U Hofmann, K Hu, F Walter, N Burkard, G Ertl, J Bauersachs, O Ritter, S Frantz and A Bonz: Pharmacological pre-and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion. Br J Pharmacol, 160(5), 1243-51 (2010)

  • [61]A Liesz, E Suri-Payer, C Veltkamp, H Doerr, C Sommer, S Rivest, T Giese and R Veltkamp: Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med, 15(2), 192-9 (2009)

  • [62]RM Monteiro, NO Camara, MM Rodrigues, F Tzelepis, MJ Damiao, MA Cenedeze, P Teixeira Vde, MA dos Reis and A Pacheco-Silva: Arole for regulatory T cells in renal acute kidney injury. Transpl Immunol, 21(1), 50-5 (2009)

  • [63]M Knapp, M Zendzian-Piotrowska, A Blachnio-Zabielska, P Zabielski, K Kurek and J Gorski: Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat. Basic Res Cardiol, 107(6), 294 (2012)

  • [64]M Knapp, M Żendzian-Piotrowska, K Kurek and A Błachnio-Zabielska: Myocardial Infarction Changes Sphingolipid Metabolism in the Uninfarcted Ventricular Wall of the Rat. Lipids, 47(9), 847-853 (2012)

  • [65]HF Duan, H Wang, J Yi, HJ Liu, QW Zhang, LB Li, T Zhang, Y Lu, CT Wu and LS Wang: Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther, 18(11), 1119-28 (2007)

  • [66]YM Klyachkin, PR Nagareddy, S Ye, M Wysoczynski, A Asfour, E Gao, M Sunkara, JA Brandon, R Annabathula, R Ponnapureddy, M Solanki, ZH Pervaiz, SS Smyth, MZ Ratajczak, AJ Morris and A Abdel-Latif: Pharmacological Elevation of Circulating Bioactive Phosphosphingolipids Enhances Myocardial Recovery After Acute Infarction. Stem Cells Transl Med (2015)

  • [67]D Goltz, S Huss, E Ramadori, R Buttner, L Diehl and R Meyer: Immunomodulation by splenectomy or by FTY720 protects the heart against ischemia reperfusion injury. Clin Exp Pharmacol Physiol, 42(11), 1168-77 (2015)

  • [68]CK Means, CY Xiao, Z Li, T Zhang, JH Omens, I Ishii, J Chun and JH Brown: Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol, 292(6), H2944-51 (2007)

  • [69]G Theilmeier, C Schmidt, J Herrmann, P Keul, M Schäfers, I Herrgott, J Mersmann, J Larmann, S Hermann, J Stypmann, O Schober, R Hildebrand, R Schulz, G Heusch, M Haude, KvW Lipinski, C Herzog, M Schmitz, R Erbel, J Chun and B Levkau: High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In vivo via the S1P3 Lysophospholipid Receptor. Circulation, 114(13), 1403-1409 (2006)

  • [70]M-C Brulhart-Meynet, V Braunersreuther, J Brinck, F Montecucco, J-C Prost, A Thomas, K Galan, G Pelli, S Pedretti, N Vuilleumier, F Mach, S Lecour, RW James and MA Frias: Improving Reconstituted HDL Composition for Efficient Post-Ischemic Reduction of Ischemia Reperfusion Injury. PLoS ONE, 10(3), e0119664 (2015)

  • [71]W Yan, F Zhang, R Zhang, X Zhang, Y Wang, F Zhou, Y Xia, P Liu, C Gao, H Wang, L Zhang, J Zhou, F Gao, E Gao, WJ Koch, H Wang, H Cheng, Y Qu and L Tao: Adiponectin regulates SR Ca(2+) cycling following ischemia/reperfusion via sphingosine 1-phosphate-CaMKII signaling in mice. J Mol Cell Cardiol, 74, 183-92 (2014)

  • [72]N Takuwa, S Ohkura, S Takashima, K Ohtani, Y Okamoto, T Tanaka, K Hirano, S Usui, F Wang, W Du, K Yoshioka, Y Banno, M Sasaki, I Ichi, M Okamura, N Sugimoto, K Mizugishi, Y Nakanuma, I Ishii, M Takamura, S Kaneko, S Kojo, K Satouchi, K Mitumori, J Chun and Y Takuwa: S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res, 85(3), 484-93 (2010)

  • [73]JA Hill and EN Olson: Cardiac plasticity. N Engl J Med, 358(13), 1370-80 (2008)

  • [74]S Spaich, HA Katus and J Backs: Ongoing controversies surrounding cardiac remodeling: is it black and white-or rather fifty shades of gray? Front Physiol, 6, 202 (2015)

  • [75]JN Cohn, R Ferrari and N Sharpe: Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol, 35(3), 569-82 (2000)

  • [76]P Robert, P Tsui, MP Laville, GP Livi, HM Sarau, A Bril and I Berrebi-Bertrand: EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol, 33(9), 1589-606 (2001)

  • [77]N Brakch, O Dormond, S Bekri, D Golshayan, M Correvon, L Mazzolai, B Steinmann and F Barbey: Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J, 31(1), 67-76 (2010)

  • [78]W Liu, M Zi, H Tsui, SK Chowdhury, L Zeef, QJ Meng, M Travis, S Prehar, A Berry, NA Hanley, L Neyses, RP Xiao, D Oceandy, Y Ke, RJ Solaro, EJ Cartwright, M Lei and X Wang: A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Circ Heart Fail, 6(4), 833-44 (2013)

  • [79]A Cannavo, G Rengo, D Liccardo, G Pagano, C Zincarelli, MC De Angelis, R Puglia, E Di Pietro, JE Rabinowitz, MV Barone, P Cirillo, B Trimarco, TM Palmer, N Ferrara, WJ Koch, D Leosco and A Rapacciuolo: β1-Adrenergic Receptor and Sphingosine-1-Phosphate Receptor 1 (S1PR1) Reciprocal Downregulation Influences Cardiac Hypertrophic Response and Progression to Heart Failure: Protective Role of S1PR1 Cardiac Gene Therapy. Circulation, 128(15), 1612-1622 (2013)

  • [80]D Fan, A Takawale, J Lee and Z Kassiri: Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis & Tissue Repair, 5(1), 15 (2012)

  • [81]I Kehat and JD Molkentin: Molecular Pathways Underlying Cardiac Remodeling During Pathophysiological Stimulation. Circulation, 122(25), 2727-2735 (2010)

  • [82]K Fujiu and R Nagai: Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol, 70, 64-73 (2014)

  • [83]LK Landeen, N Aroonsakool, JH Haga, BS Hu and WR Giles: Sphingosine-1-phosphate receptor expression in cardiac fibroblasts is modulated by in vitro culture conditions. Am J Physiol Heart Circ Physiol, 292(6), H2698-711 (2007)

  • [84]N Gellings Lowe, JS Swaney, KM Moreno and RA Sabbadini: Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovasc Res, 82(2), 303-12 (2009)

  • [85]D Pchejetski, C Foussal, C Alfarano, O Lairez, D Calise, C Guilbeau-Frugier, S Schaak, MH Seguelas, E Wanecq, P Valet, A Parini and O Kunduzova: Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J, 33(18), 2360-9 (2012)

  • [86]A Frati, B Ricci, F Pierucci, S Nistri, D Bani and E Meacci: Role of sphingosine kinase/S1P axis in ECM remodeling of cardiac cells elicited by relaxin. Mol Endocrinol, 29(1), 53-67 (2015)

  • [87]N Benamer, N Fares, P Bois and JF Faivre: Electrophysiological and functional effects of sphingosine-1-phosphate in mouse ventricular fibroblasts. Biochem Biophys Res Commun, 408(1), 6-11 (2011)

  • [88]D Kerage, DN Brindley and DG Hemmings: Review: novel insights into the regulation of vascular tone by sphingosine 1-phosphate. Placenta, 35Suppl, S86-92 (2014)

  • [89]Y Takuwa, Y Okamoto, K Yoshioka and N Takuwa: Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta, 1781(9), 483-8 (2008)

  • [90]J Igarashi and T Michel: Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc Res, 82(2), 212-20 (2009)

  • [91]M Schuchardt, M Tolle, J Prufer and M van der Giet: Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system. Br J Pharmacol, 163(6), 1140-62 (2011)

  • [92]A Skoura and T Hla: Lysophospholipid receptors in vertebrate development, physiology, and pathology. J Lipid Res, 50 Suppl, S293-8 (2009)

  • [93]Z Guan, ST Singletary, AK Cook, JL Hobbs, JS Pollock and EW Inscho: Sphingosine-1-phosphate evokes unique segment-specific vasoconstriction of the renal microvasculature. J Am Soc Nephrol, 25(8), 1774-85 (2014)

  • [94]B Wang, J Jiang, Z Fan, R Jiang, R Wang and H Lin: Expression of Sphingosine 1-Phosphate 1-3 on Penile Cavernous Tissue in Hypertensive and Normotensive Rats. Urology, 84(2), 490.e7-490.e13 (2014)

  • [95]C Tabeling, H Yu, L Wang, H Ranke, NM Goldenberg, D Zabini, E Noe, A Krauszman, B Gutbier, J Yin, M Schaefer, C Arenz, AC Hocke, N Suttorp, RL Proia, M Witzenrath and WM Kuebler: CFTR and sphingolipids mediate hypoxic pulmonary vasoconstriction. Proc Natl Acad Sci U S A, 112(13), E1614-23 (2015)

  • [96]M Ksiazek, M Chacinska, A Chabowski and M Baranowski: Sources, metabolism, and regulation of circulating sphingosine-1-phosphate. J Lipid Res, 56(7), 1271-81 (2015)

  • [97]F Poti, M Simoni and JR Nofer: Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovasc Res, 103(3), 395-404 (2014)

  • [98]F Poti, U Ceglarek, R Burkhardt, M Simoni and JR Nofer: SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet. Atherosclerosis, 240(1), 212-5 (2015)

  • [99]M Bot, PP Van Veldhoven, SC de Jager, J Johnson, N Nijstad, PJ Van Santbrink, MM Westra, G Van Der Hoeven, MJ Gijbels, C Muller-Tidow, G Varga, UJ Tietge, J Kuiper, TJ Van Berkel, JR Nofer, I Bot and EA Biessen: Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDL-receptor deficient mice. PLoS One, 8(5), e63360 (2013)

  • [100]H Xu, Y Jin, H Ni, S Hu and Q Zhang: Sphingosine-1-phosphate receptor agonist, FTY720, restores coronary flow reserve in diabetic rats. Circ J, 78(12), 2979-86 (2014)

  • [101]XC Jiang and J Liu: Sphingolipid metabolism and atherosclerosis. Handb Exp Pharmacol(216), 133-46 (2013)

  • [102]M Fenger, A Linneberg and J Jeppesen: Network-based analysis of the sphingolipid metabolism in hypertension. Front Genet, 6, 84 (2015)

  • [103]M Fenger, A Linneberg, T Jorgensen, S Madsbad, K Sobye, J Eugen-Olsen and J Jeppesen: Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension. BMC Genet, 12, 44 (2011)

  • [104]J Camm, T Hla, R Bakshi and V Brinkmann: Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J, 168(5), 632-44 (2014)

  • [105]A Cantalupo, Y Zhang, M Kothiya, S Galvani, H Obinata, M Bucci, FJ Giordano, X-C Jiang, T Hla and A Di Lorenzo: Nogo-B regulates endothelial sphingolipid homeostasis to control vascular function and blood pressure. Nat Med, 21(9), 1028-1037 (2015)

  • [106]PC Wilson, WR Fitzgibbon, SM Garrett, AA Jaffa, LM Luttrell, MW Brands and HM El-Shewy: Inhibition of Sphingosine Kinase 1 Ameliorates Angiotensin II-Induced Hypertension and Inhibits Transmembrane Calcium Entry via Store-Operated Calcium Channel. Mol Endocrinol, 29(6), 896-908 (2015)

  • [107]H Furuya, M Wada, Y Shimizu, PM Yamada, YA Hannun, LM Obeid and T Kawamori: Effect of sphingosine kinase 1 inhibition on blood pressure. Faseb j, 27(2), 656-64 (2013)

  • [108]MJ Kluk and T Hla: Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta, 1582(1-3), 72-80 (2002)

  • [109]MM Facchinetti, F Leocata Nieto, MG Marquez and N Sterin-Speziale: Stratification of sphingosine kinase-1 expression and activity in rat kidney. Cells Tissues Organs, 188(4), 384-92 (2008)

  • [110]R Alemany, CJ van Koppen, K Danneberg, M Ter Braak and D Meyer Zu Heringdorf: Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol, 374(5-6), 413-28 (2007)

  • [111]A Bischoff, P Czyborra, D Meyer Zu Heringdorf, KH Jakobs and MC Michel: Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br J Pharmacol, 130(8), 1878-83 (2000)

  • [112]A Bischoff, D Meyer Zu Heringdorf, KH Jakobs and MC Michel: Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats. Br J Pharmacol, 132(8), 1925-33 (2001)

  • [113]C Czyborra, A Bischoff and MC Michel: Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine. Naunyn Schmiedebergs Arch Pharmacol, 373(1), 37-44 (2006)

  • [114]Q Zhu, M Xia, Z Wang, PL Li and N Li: A novel lipid natriuretic factor in the renal medulla: sphingosine-1-phosphate. Am J Physiol Renal Physiol, 301(1), F35-41 (2011)

  • [115]E Fuentes and I Palomo: Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk. Thromb Res, 134(2), 221-6 (2014)

  • [116]SS Stojilkovic, T Murano, AE Gonzalez-Iglesias, SA Andric, MA Popovic, F Van Goor and M Tomic: Multiple roles of Gi/o protein-coupled receptors in control of action potential secretion coupling in pituitary lactotrophs. Ann N Y Acad Sci, 1152, 174-86 (2009)

  • [117]DJ Benos, MS Awayda, BK Berdiev, AL Bradford, CM Fuller, O Senyk and Ismailov, II: Diversity and regulation of amiloride-sensitive Na+ channels. Kidney Int, 49(6), 1632-7 (1996)

  • [118]D Graham, MW McBride, M Gaasenbeek, K Gilday, E Beattie, WH Miller, JD McClure, JM Polke, A Montezano, RM Touyz and AF Dominiczak: Candidate Genes That Determine Response to Salt in the Stroke-Prone Spontaneously Hypertensive Rat: Congenic Analysis. Hypertension, 50(6), 1134-1141 (2007)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Review

Implication of sphingosin-1-phosphate in cardiovascular regulation

Ningjun Li 1,*, Fan Zhang 1
Affiliation
Article Info

1 Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia, USA

Abstract

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite generated by phosphorylation of sphingosine catalyzed by sphingosine kinase. S1P acts mainly through its high affinity G-protein-coupled receptors and participates in the regulation of multiple systems, including cardiovascular system. It has been shown that S1P signaling is involved in the regulation of cardiac chronotropy and inotropy and contributes to cardioprotection as well as cardiac remodeling; S1P signaling regulates vascular function, such as vascular tone and endothelial barrier, and possesses an anti-atherosclerotic effect; S1P signaling is also implicated in the regulation of blood pressure. Therefore, manipulation of S1P signaling may offer novel therapeutic approaches to cardiovascular diseases. As several S1P receptor modulators and sphingosine kinase inhibitors have been approved or under clinical trials for the treatment of other diseases, it may expedite the test and implementation of these S1P-based drugs in cardiovascular diseases.

Keywords

  • Review
  • Sphingosine Kinase
  • Blood Pressure
  • Cardiac Remodeling
  • Atherosclerosis
  • Sodium Excretion
  • Vascular Tone
  • Endothelial Permeability

References